(Q37734553)

22 August 2017

1 reference

title

Anacetrapib: hope for CETP inhibitors? (English)

1 reference

22 August 2017

Ronen Gurfinkel

1

1 reference

PubMed ID

20406242

22 August 2017

Tisha R Joy

series ordinal

2

1 reference

22 August 2017

9 April 2010

1 reference

Cardiovascular Therapeutics

22 August 2017

1 reference

22 August 2017

29

1 reference

22 August 2017

5

1 reference

22 August 2017

327-339

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

22 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Is raising HDL a futile strategy for atheroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00142.X

10.1111/J.1755-5922.2010.00142.X

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20406242